Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07283692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Feb 2026 to Mar 1, 2026
    • Site details revised
    v3
  2. Start date: Dec 2025 to Feb 2026
    • Primary endpoint revised
    • Secondary endpoint revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Trial Details
NCT Number NCT07283692
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 Triple Negative Breast Cancer
Related terms Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov